Here, we confirmed that CD44v6 was highly expressed in FLT3 or DNMT3A mutant AML cell lines or primary AML cells, whereas it was absent in normal HSCs, proving that CD44v6 was an ideal target for AML patients with FLT3 and DNMT3A mutations. This evidence concerns the gene FLT3 and acute myeloid leukemia.